Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer
Circulating tumour DNA (ctDNA) has clinical applications as a “liquid biopsy” owing to its short half-life, noninvasive collection modalities, and propensity for sampling across populations of tumour cells [1]. While successful ctDNA detection has been demonstrated in metastatic prostate cancer [2], localised disease yields low levels of ctDNA, making detection difficult using conventional methods [3].